Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 609Breast Neoplasms 606Colorectal Neoplasms 457Neoplasm Metastasis 395Ovarian Neoplasms 327Prostatic Neoplasms 314Melanoma 311Lung Neoplasms 295Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 227Leukemia, Myeloid, Acute 221Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 181Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 179Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 155Lymphoma, Follicular 149Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, T-Cell × 1 year × Clear all
NCT04329728 2026-04-15

OPAL

AVM Biotechnology Inc

Phase 1/2 Recruiting
144 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07471789 2026-03-13

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Gyala Therapeutics

Phase 1/2 Recruiting
33 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡